Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market to Reach US$ 26.2 Bn in 2027; Drug Makers Focus on Combination Therapies: Transparency Market Research
- Healthcare providers are constantly seeking new treatment avenues by trying new combination therapies in the Chronic Obstructive Pulmonary Disease (COPD) treatment market
- Clinical studies focus on preventing moderate-to-severe COPD exacerbations, particularly by improving the classes of bronchodilators; patent expiry of branded products can hamper profitability of players
ALBANY, New York, Feb. 26, 2020 /PRNewswire/ -- Growing burden of Chronic Obstructive Pulmonary Disease (COPD) globally has advanced our understanding of treatment options, especially in relation to triple combination therapies. With the key focus on reducing the mortality of COPD patients worldwide, the COPD treatment market is expected to clock CAGR of ~5% from 2019 to 2027, notes a study by Transparency Market Research (TMR).
In 2018, the market's valuation was pegged at ~US$ 17.4 bn, and is projected to reach worth of US$ 26.2 billion by 2027-end.
Researchers are relentlessly working to improve the efficacy of combinations of bronchodilators in managing COPD exacerbations. In this regard, triple therapies with better outcomes have attracted the attention of healthcare providers and clinicians in the COPD treatment market. The need for combined bronchodilator response (BDR) in patients will open new avenues in the market.
"In forthcoming years, online pharmacies are likely to witness a promising growth in the COPD market. Healthcare companies are leaning on adopting therapies that reduce the bronchodilator reversibility in patients. Thus, manufacturers should focus on developing better triple therapy treatments to effectively manage COPD exacerbations," opine the analysts in TMR. https://www.transparencymarketresearch.com/report-toc/73763
Key Findings of Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Study
Of all the drug classes in the COPD treatment market, revenue contribution from the combination therapies segment was the largest in 2018--US$ 9.6 bn. Such therapies are remarkably helpful in improving the quality of life of the patients
Bronchodilators come second among the key drug classes; the segment is anticipated to reach revenues valuation of ~US$ 5.5 billion by 2027-end. Advancements in combined bronchodilator response in patients with COPD have helped healthcare providers reduce the morbidity and mortality
Triple therapy has been associated with superior outcome to single-agent LAMA monotherapy, particularly in reducing moderate-to-severe COPD exacerbations in the patient population
Combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA) are effective in managing symptomatic COPD.
Explore 193 pages of top-notch research, incisive insights, and detailed country-level projections. Gain business intelligence on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market (Drug Class: Combination Therapy, Corticosteroids, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Bronchodilators, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73763
COPD Treatment Market: Key Driving Factors
COPD has emerged as the most prevalent chronic respiratory ailment, and the disease is one of the primary causes of morbidity and mortality worldwide. In several parts of the world, its prevalence and mortality rate has been rising. Healthcare costs—both direct and indirect—with COPD have been rising, particularly from acute exacerbations. Numerous such trends have shaped the evolution of the COPD treatment market. Increase in risk factors particularly smoking play crucial role in expanding the market potential. A spate of studies have shed light on the growing morbidity of COPD.
Per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2018, focused on increasing the awareness of the prevalence of COPD, the prevalence of and economic burden from COPD are expected to rise in next few years.
In the U.S., COPD is the third leading cause of death, propelling advances in understanding the disease epidemiology.
Rapidly aging populations in various parts of the world is expected to increase the caseload of COPD with clinics, thus driving the demand for more efficacious treatments.
Worldwide, numbers of patients who have responded well to combination therapy are boosting prospects of the COPD treatment market.
Key Impediments to COPD Treatment Market Players
Branded drugs have been source of substantial revenues to the COPD treatment market. However, the patent expiry in near future is a key impediment to the expansion of revenues from companies holding these patents. Moreover, the advent of generic drugs has hurt the profitability of players, as it creates an adverse bearing on manufactures setting price of drugs. Such pricing pressure are imminent in North America and Europe.
Analyze COPD treatment market growth in 30+ countries including US, Canada, Germany, United Kingdom, GCC countries, India, China, and Japan. Request a sample of the study
COPD Treatment Market: Region-wise Analysis
Favorable regulatory frameworks in Asia-Pacific, Europe, and North America and constant array of new drug formulation in their economies make these regions increasingly lucrative markets. Most of these have focused on supporting the approval of combination drugs for COPD treatment. Over the past few years, the FDA, and the European Commission, and the Ministry of Health, Labour and Welfare (MHLW) in Japan, have helped drug makers to flourish in the COPD treatment market. Further, growing understanding of the prevalence of and burden from COPD has cemented the potential of the North America market.
Key players in the COPD treatment market are focusing on unveiling new products. Additionally, they are engaging in mergers and acquisitions, and undertaking license agreement as part of strategic collaborations. A few players are also relying on acquisitions in order to consolidate their product portfolio in the respiratory business, hence strengthening their positions in the COPD treatment market.
Some of the promising players in the COPD treatment market are Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., AstraZeneca, and Orion Corporation.
Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
Phosphodiesterase Type 4 Inhibitors
Long Acting Beta Agonist (LABA)
Short Acting Beta Agonist (SABA)
Long Acting Muscarinic Antagonist (LAMA)
COPD Treatment Market by Distribution Channel
COPD Treatment Market by Region
Russia & CIS
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East & Africa
Rest of Middle East & Africa
Explore Transparency Market Research's award-winning coverage of the global Healthcare industry:
Metered Dose Inhalers Market - Metered dose inhalers are the most common type of inhalers used in asthmatic conditions. Spacer is an external device attached to the MDI, which provides better drug delivery by enhancing inhalation and actuation. The major advantage of aerosol drug delivery is fast onset of therapeutic action as the drug is delivered to the target site of action.
Bronchodilators Market - The global bronchodilators market is majorly driven by an increasing focus on the development of monoclonal antibody therapy. Monoclonal antibody therapy is increasingly being used for the treatment of diseases such as tumour, which in turn has inspired market players to double their efforts and focus on the development of monoclonal antibody therapy. The positive results shown by monoclonal antibody therapy is expected to increase its uptake.
Emphysema Market - Smoking is one of the major causes of emphysema among vast majority of population. As per the studies conducted smokers are six times more likely to be victim of emphysema as compared to non smokers. Apart from smoking alpha-1 antitrypsin (AAT) deficiency is another cause of emphysema.
Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: [email protected]